Abivax stock tumbles after Scorpion Capital report questions obefazimod safety
In short
Market valuation for Abivax declined sharply following the publication of critical research by Scorpion Capital. The published document concentrated specifically on the overall safety profile of the investigational drug candidate obefazimod. These emerging questions regarding safety have introduced new risks for the development candidate.
Key points
- Negative findings published by Scorpion Capital triggered an immediate and sharp market d…: Negative findings published by Scorpion Capital triggered an immediate and sharp market decline for Abivax.
- The company faces serious scrutiny regarding the documented safety profile of its drug ca…: The company faces serious scrutiny regarding the documented safety profile of its drug candidate obefazimod.
- Investor sentiment has been disrupted by emerging doubts surrounding the clinical profile…: Investor sentiment has been disrupted by emerging doubts surrounding the clinical profile of the drug candidate.